Article focus {#section5-2046-3758.65.BJR-2017-0276.R1}
=============

-   Comprehensive data describing thermal stability of antibiotic agents in aqueous solution at physiological temperature for local application in orthopaedic indications are not available.

-   Thermal stability at 37°C of 37 antibiotic drugs over six weeks is described.

-   As bone cement is frequently used in orthopaedic surgery for the local delivery of antibiotics, the potential effect of the exothermic curing process of bone cement on antibiotic agents was also examined.

Key messages {#section6-2046-3758.65.BJR-2017-0276.R1}
============

-   Aminoglycosides, glycopeptides, tetracyclines and quinolones have good thermal stability over six weeks, but local toxicity issues might limit local application of tetracyclines and quinolones.

-   While beta-lactams show exponential degradation over time, sustained antibacterial activity can be observed for up to three weeks, with aztreonam displaying even greater stability.

-   The heat generated by curing bone cement does not have any effect on the majority of the antibiotic agents tested, except for gentamicin, that degraded by approximately 25%.

Strengths and limitations {#section7-2046-3758.65.BJR-2017-0276.R1}
=========================

-   Two analytical methods have been used: qualitative assessment of antimicrobial activity by disk diffusion tests; and quantification by liquid chromatography coupled to mass spectrometry, or fluorescence polarisation immunoassays, as available.

-   Degradation half-lives have been calculated from quantification data, but these methods were available for only 20 antibiotics.

-   Antibacterial activity has been tested by the Kirby-Bauer disk diffusion assay, but interpretation of inhibition zone results has limitations, particularly as some substances have inconstant diffusion or degradation on agar.

Introduction {#section8-2046-3758.65.BJR-2017-0276.R1}
============

Local delivery of antibiotics enables high drug concentrations to be achieved at the desired site of antimicrobial action, while keeping systemic exposure and toxicity low.^[@bibr1-2046-3758.65.BJR-2017-0276.R1]-[@bibr3-2046-3758.65.BJR-2017-0276.R1]^ The following characteristics are desirable for a given antimicrobial agent to be suitable for local application: adequate antimicrobial spectrum; chemical compatibility with, and adequate release kinetics from the chosen carrier; appropriate solubility; low local toxicity; low systemic exposure and/or toxicity; and low risk of hypersensitivity.^[@bibr1-2046-3758.65.BJR-2017-0276.R1]-[@bibr5-2046-3758.65.BJR-2017-0276.R1]^ Thermal stability is a key factor in determining an antibiotic's suitability for local application, as it must not only resist any heat generated during the manufacturing process of the carrier, but also be stable at body temperature over the entire duration of the release period inside the patient.^[@bibr2-2046-3758.65.BJR-2017-0276.R1],[@bibr4-2046-3758.65.BJR-2017-0276.R1]^ Despite the growing use of locally delivered antimicrobial agents, data regarding thermal stability in such settings are incomplete, scarce or even lacking entirely.

A large number of studies have been published that examine drug release *in vitro* and *in vivo* from various carrier materials.^[@bibr3-2046-3758.65.BJR-2017-0276.R1],[@bibr5-2046-3758.65.BJR-2017-0276.R1]-[@bibr9-2046-3758.65.BJR-2017-0276.R1]^ However, these studies primarily tested compatibility with carrier substances and were designed to quantify the amount of antibiotic released from the matrix. The most commonly tested condition is antibiotic release from bone cement (polymethyl methacrylate, PMMA), which has been shown to release antibiotic over a number of weeks.^[@bibr6-2046-3758.65.BJR-2017-0276.R1]^ However, such data are specific to the formulation of the bone cement and do not translate to other materials. Overall, the limited data available at present have studied antibiotic stability over a short period of time and below body temperature or with a restricted range of antibiotics.^[@bibr10-2046-3758.65.BJR-2017-0276.R1]^ Such studies have generally been performed with the purpose of testing portable infusion devices for prolonged intravenous antibiotic therapy in an outpatient setting, for continuous antibiotic infusion to optimise antimicrobial pharmacodynamics in critical care, or for the use of antibiotics in peritoneal dialysis solution.^[@bibr11-2046-3758.65.BJR-2017-0276.R1]-[@bibr16-2046-3758.65.BJR-2017-0276.R1]^ Information regarding thermal stability of antibiotics exposed to body temperature over a prolonged period is thus necessary for a comprehensive assessment of the suitability of their use for local application.

The primary aim of this study was therefore to examine the stability of solutions of 38 antibiotics maintained at 37°C for six weeks, a common duration of treatment in the orthopaedic setting.^[@bibr17-2046-3758.65.BJR-2017-0276.R1],[@bibr18-2046-3758.65.BJR-2017-0276.R1]^ Such data are critical for any future controlled extended release antibiotic delivery vehicle. As PMMA remains the most frequently used carrier material in orthopaedic applications,^[@bibr3-2046-3758.65.BJR-2017-0276.R1]-[@bibr5-2046-3758.65.BJR-2017-0276.R1]^ the secondary objective of this study was to examine the impact of an initial thermal treatment simulating the exothermic process of PMMA polymerisation, followed by exposure to 37°C for six weeks, on antibiotic stability. This study will therefore provide an overview of the thermal stability of a broad range of antibiotics, helping to guide clinicians in selecting the most appropriate agents for local application.

Materials and Methods {#section9-2046-3758.65.BJR-2017-0276.R1}
=====================

Antibiotic agents {#section10-2046-3758.65.BJR-2017-0276.R1}
-----------------

Antibiotic agents were selected on the basis of clinical experience in local application, published experimental data, and potential for local application based on chemical properties and antimicrobial mode of action. Preference was given to clinically available antibiotic preparations, rather than analytical or research preparations. Solutions were used only if no powdered form was available. A total of 38 antibiotic agents were included, five of which were combination products. The combination products involved either two partner antibiotics or one antibiotic with an enzyme inhibitor. In the case of combination products, only the antibiotic agent(s) for which an analytical methodology was available were measured. A comprehensive list is provided in [Table I](#table1-2046-3758.65.BJR-2017-0276.R1){ref-type="table"}. Each antibiotic was dissolved or diluted in 0.9 % w/v NaCl (B. Braun Medical, Sempach, Switzerland) to an arbitrary initial target concentration of 200 mg/l. The prepared solutions, therefore, contained the antibiotic drug as well as any excipients present in the pharmaceutical formulations. Details of preservatives and excipients present in the antibiotic may be found, where present, on the package inserts. Antibiotics were generally available as salt, and less frequently as base or acid. Each antibiotic solution was divided into two equal portions immediately after preparation. One portion was directly incubated at 37°C for 42 days (Regular group) and the second exposed to a thermal curve mimicking the exothermic bone cement curing process (as described below), followed by incubation at 37°C for 42 days (Heat group). Aliquots of the antibiotic solution were taken after preparation, and again after 12 and 24 hours, and at two, three, five, seven, 14, 21 and 42 days. At each time point, triplicate 1 ml aliquots were withdrawn and frozen in cryotubes (Thermo Fisher Scientific (Schweiz), Reinach, Switzerland), and stored at -80°C until analysis. Samples were analysed as a single batch upon completion of the study.

###### 

List of tested antibiotics and corresponding methods for measuring drug concentration and antimicrobial activity

  Antibiotic                             Brand name (Supplier)                                                           Quantification   Disk Diffusion
  -------------------------------------- ------------------------------------------------------------------------------- ---------------- ------------------------
  **Penicillins**                                                                                                                         
  Amoxicillin                            Clamoxyl (GlaxoSmithKline, Münchenbuchsee, Switzerland)                         LC-MS/MS         *S. aureus* NCTC 12973
  Amoxicillin+clavulanate                Co-Amoxi-Mepha (Mepha Pharma, Basel, Switzerland)                                                *S. aureus* NCTC 12973
  Flucloxacillin                         Floxapen (Actavis, Regensdorf, Switzerland)                                     LC-MS/MS         *S. aureus* NCTC 12973
  Ticarcillin+clavulanate                Timentin (GlaxoSmithKline, Brentford, United Kingdom)                                            *S. aureus* NCTC 12973
  Temocillin                             Negaban (Eumedica, Manage, Belgium)                                                              *E. coli* NCTC 12241
  Piperacillin+tazobactam                Piperacillin Tazobactam (Sandoz Pharmaceuticals, Risch-Rotkreuz, Switzerland)   LC-MS/MS         *S. aureus* NCTC 12973
  **Cephalosporins**                                                                                                                      
  Cefazolin                              Kefzol (Teva Pharma, Basel, Switzerland)                                        LC-MS/MS         *S. aureus* NCTC 12973
  Cefuroxime                             Zinacef (GlaxoSmithKline, Münchenbuchsee, Switzerland)                          LC-MS/MS         *S. aureus* NCTC 12973
  Cefotaxime                             Claforan (Sanofi-Aventis, Vernier, Switzerland)                                                  *S. aureus* NCTC 12973
  Ceftriaxone                            Rocephin (Roche Pharma, Reinach, Switzerland)                                   LC-MS/MS         *S. aureus* NCTC 12973
  Ceftazidime                            Fortam (GlaxoSmithKline, Münchenbuchsee, Switzerland)                           LC-MS/MS         *S. aureus* NCTC 12973
  Cefepime                               Cefepime OrPha (OrPha Swiss, Küsnacht, Switzerland)                             LC-MS/MS         *S. aureus* NCTC 12973
  **Carbapenems and monobactams**                                                                                                         
  Imipenem+cilastatin                    Imipenem-Cilastatin Labatec (Labatec Pharma, Meyrin, Switzerland)               LC-MS/MS         *S. aureus* NCTC 12973
  Meropenem                              Meropenem Labatec (Labatec Pharma, Meyrin, Switzerland)                         LC-MS/MS         *S. aureus* NCTC 12973
  Ertapenem                              Invanz (Merck & Co, Lucerne, Switzerland)                                       LC-MS/MS         *S. aureus* NCTC 12973
  Aztreonam                              Azactam (Bristol-Myers Squibb, Cham, Switzerland)                                                *E. coli* NCTC 12241
  **Glycopeptides and lipopeptides**                                                                                                      
  Vancomycin                             Vancocin (Teva Pharma, Basel, Switzerland)                                      LC-MS/MS         *S. aureus* NCTC 12973
  Teicoplanin                            Teicoplanin Labatec (Labatec Pharma, Meyrin, Switzerland)                                        *S. aureus* NCTC 12973
  Telavancin                             Vibativ (Theravance, San Francisco, California)                                                  *S. aureus* NCTC 12973
  Daptomycin                             Cubicin (Novartis Pharma, Basel, Switzerland)                                   LC-MS/MS         *S. aureus* NCTC 12973
  **Aminoglycosides**                                                                                                                     
  Amikacin                               Amikin (Bristol-Myers Squibb, Cham, Switzerland)                                FPIA             *S. aureus* NCTC 12973
  Gentamicin                             Gentamicin-MP (InfectoPharm, Heppenheim, Germany)                               FPIA             *S. aureus* NCTC 12973
  Tobramycin                             Obracin (Teva Pharma, Basel, Switzerland)                                       FPIA             *S. aureus* NCTC 12973
  Quinolones                                                                                                                              
  Ciprofloxacin                          Ciproxine (Bayer, Zürich, Switzerland)                                          LC-MS/MS         *S. aureus* NCTC 12973
  Levofloxacin                           Tavanic (Sanofi-Aventis, Vernier, Switzerland)                                  LC-MS/MS         *S. aureus* NCTC 12973
  Moxifloxacin                           Avalox (Bayer, Zürich, Switzerland)                                                              *S. aureus* NCTC 12973
  **Macrolides and ketolides**                                                                                                            
  Erythromycin                           Erythrocine (Pro Concepta, Zug, Switzerland)                                                     *S. aureus* NCTC 12973
  Clarithromycin                         Klacid (Abbott, Baar, Switzerland)                                                               *S. aureus* NCTC 12973
  Azithromycin                           Zithromax (Pfizer, Zürich, Switzerland)                                                          *S. aureus* NCTC 12973
  Telithromycin                          Ketek (Sanofi-Aventis, Vernier, Switzerland)                                                     *S. aureus* NCTC 12973
  **Tetracyclines and glycylcyclines**                                                                                                    
  Doxycycline                            Vibravenös (Pfizer, Zürich, Switzerland)                                                         *S. aureus* NCTC 12973
  Minocycline                            Minac (Spirig Pharma, Egerkingen, Switzerland)                                                   *S. aureus* NCTC 12973
  **Various**                                                                                                                             
  Rifampin                               Rimactan (Sandoz Pharmaceuticals, Risch, Switzerland)                           LC-MS/MS         *S. aureus* NCTC 12973
  Clindamycin                            Clindamycin (Sandoz)                                                            LC-MS/MS         *S. aureus* NCTC 12973
  Linezolid                              Zyvoxid (Pfizer, Zürich, Switzerland)                                           LC-MS/MS         *S. aureus* NCTC 12973
  Fusidic acid                           Fucidin (Leo Pharmaceuticals, Regensdorf-Watt, Switzerland)                                      *S. aureus* NCTC 12973
  Trimethoprim with sulfamethoxazole     Bactrim (Roche Pharma, Reinach, Switzerland)                                                     *S. aureus* NCTC 12973
  Colistimethate                         Colistin (Forest Laboratories, Zürich, Switzerland)                             LC-MS/MS         *P. aeruginosa* PAO1

LC-MS/MS, High-performance liquid chromatography coupled to tandem mass spectrometry; FPIA, fluorescence polarisation immunoassay; DD, disk diffusion; NCTC, national collection of type cultures.

Temperature monitoring and exposure: determination of temperature-time profile during PMMA polymerisation {#section11-2046-3758.65.BJR-2017-0276.R1}
---------------------------------------------------------------------------------------------------------

A 40 g package of commercially available high viscosity bone cement (Palacos R; Heraeus Medical, Wehrheim, Germany) was prepared according to manufacturer instructions using manual mixing. The cement dough was then poured into a 60 ml syringe. A thermocouple sensor (Type K Thermocouple; Pico Technology, Eaton Socon, United Kingdom) was inserted 5 mm into the cement, and the second sensor recorded ambient air temperature. After 12 minutes, when the cement had hardened, the syringe was removed and the cement block, with the thermocouple still in place, was immersed in a water bath at 37°C (Sonorex Super; Bandelin electronic, Berlin, Germany) to mimic the positioning of a formed cement spacer in the human body. Cement and water temperature were measured at 15 second intervals (recorded by USB TC-08 Thermocouple Data Logger and PicoLog data acquisition, Pico Technology). The experiment was performed in triplicate.

Temperature monitoring and exposure : heat exposure mimicking PMMA polymerisation {#section12-2046-3758.65.BJR-2017-0276.R1}
---------------------------------------------------------------------------------

A steam autoclave (Vitaris, Münchenstein, Switzerland) was used to subject test solutions to a heat programme that would mimic the observed temperature-time profile of curing cement. Glass bottles containing 150 ml of antibiotic solution were placed in the pre-warmed autoclave. Temperature monitoring in the liquid was performed through a thermocouple sensor directly immersed in 0.9% NaCl solution, with measurements recorded every 15 seconds. Once a maximum chamber temperature of 83°C had been reached and maintained for 60 seconds, the solutions were removed and exposed to ambient air for three minutes. Subsequently, the bottles were immersed in a water bath at 17°C. Temperatures were recorded every 15 seconds from commencement of the heat cycle until the temperature of 37°C was reached. The water bath was set to 17°C in order to accept the heat transfer from the antibiotic solution-containing bottles, and still achieve the target of 37°C within a time-frame closely matching curing PMMA. The target chamber temperature of 83°C was set so that the solution may exceed this temperature, but still not reach boiling point. The above-described heat cycle has been chosen to follow as closely as possible the heat-time profile of curing PMMA, without causing the test solutions to boil.

Assessment of antibiotic concentration and activity: high performance liquid chromatography coupled to tandem mass spectrometry {#section13-2046-3758.65.BJR-2017-0276.R1}
-------------------------------------------------------------------------------------------------------------------------------

The concentrations of 19 antibiotic agents were measured by high-performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) using adaptations of validated methods used in therapeutic drug monitoring in patients, or by specifically developing LC-MS/MS assays for this project ([Table I](#table1-2046-3758.65.BJR-2017-0276.R1){ref-type="table"}). Antibiotic drug concentrations were determined from samples, thawed and analysed as a single batch after appropriate dilution of aliquots, collected at 0 hour and at days one, three, seven and 42. Reverse-phase chromatographic separation of antibiotics was obtained using stepwise gradient elution of the mobile phase, consisting of 10 mM ammonium formate solution with 0.4% formic acid and acetonitrile delivered onto a 1.8 µm UPLC column Waters Acquity UPLC HSS T3 2.1 x 50 mm (Waters Corp., Milford, Massachusetts).

Detection was performed by electrospray ionisation--triple quadrupole mass spectrometry on Quantum mass spectrometers (Thermo Fisher Scientific, Waltham, Massachusetts), by selected reaction monitoring detection, using the specific antibiotic transitions in the positive mode, except for cefuroxime (negative mode, as cefuroxime is negatively charged after ionisation). Antibiotic quantification was performed using matrix-matched calibration samples using the stable isotopically labelled internal standard of each antibiotic (except for vancomycin, for which no labelled internal standard was available and therefore an external calibration was applied). The lower limits of quantification (LOQ) range from 0.02 mg/l to 1 mg/l. Individual LOQ limits were 0.02 mg/l for rifampin, 0.05 mg/l for cefazolin, cefepime, imipenem, meropenem, tazobactam, and colistin, 0.08 mg/l for piperacillin, 0.1 mg/l for amoxicillin, flucloxacillin, cefuroxime, ceftazidime, ertapenem, ciprofloxacin, levofloxacin, clindamycin, and linezolid, 0.5 mg/l for ceftriaxone and daptomycin, and 1 mg/l for vancomycin.

Assessment of antibiotic concentration and activity: fluorescence polarisation immunoassays {#section14-2046-3758.65.BJR-2017-0276.R1}
-------------------------------------------------------------------------------------------

The concentrations of gentamicin, tobramycin and amikacin were measured by fluorescence polarisation immunoassay (FPIA) on a Cobas Integra 400 plus (Roche Diagnostics International, Rotkreuz, Switzerland) using the standard reagents of the commercial kit. Appropriate dilution of test solutions was performed with human plasma since immunoassays can only be performed in the same biological matrix that is used for calibration. The LOQ was 0.5 mg/l, 0.74 mg/l and 2.5 mg/l for gentamicin, tobramycin and amikacin, respectively.

Assessment of antibiotic concentration and activity: disk diffusion test {#section15-2046-3758.65.BJR-2017-0276.R1}
------------------------------------------------------------------------

Antimicrobial activity of all antibiotic solutions was measured by the Kirby-Bauer disk diffusion method, performed following the European Committee on Antimicrobial Susceptibility Testing (EUCAST) protocol.^[@bibr19-2046-3758.65.BJR-2017-0276.R1],[@bibr20-2046-3758.65.BJR-2017-0276.R1]^ Reference strains *E. coli* NCTC 12241, *P. aeruginosa* PAO1, or *S. aureus* NCTC 12973, were chosen depending on the spectrum of activity of the antibiotic tested, and are shown in [Table I](#table1-2046-3758.65.BJR-2017-0276.R1){ref-type="table"}. Samples were tested in triplicate using 7 mm paper disks (Becton Dickinson, Heidelberg, Germany), impregnated with 20 µl sample solution. The disks were placed on circular Petri dishes with 25 ml Mueller Hinton agar (Thermo Fisher Scientific Oxoid Ltd, Basingstoke, United Kingdom), which was inoculated with a suspension of the reference organism. Each test batch included a control disk containing 10 µg gentamicin (Becton Dickinson) to ascertain proper preparation and application of the bacterial suspension. Plates were incubated at 37°C for 20 hours, at which time zones of inhibition (ZOI) were measured to the nearest whole millimetre.

Data analysis {#section16-2046-3758.65.BJR-2017-0276.R1}
-------------

Mean values and standard deviations have been calculated from triplicate samples, for the results from LC-MS/MS, FPIA, and also disk diffusion assays. The results of LC-MS/MS or FPIA quantifications were expressed as a percentage of the initial concentration, i.e. without the initial heat exposure. A two-way ANOVA was used to compare differences between the regular and body temperature groups for the LC-MS/MS data. Sidak\'s *post hoc* test was used to control for multiple comparisons. The results from the disk diffusion tests are indicated as diameter of the zone of inhibition. A two-way ANOVA was used to compare differences between the ZOI diameter over time. In all cases, significance was accepted at p \< 0.05. Prism software was used for all statistical tests (GraphPad Software, La Jolla, California). The *in vitro* half-lives (t~1/2~) of the antibiotics measured using LC-MS/MS were calculated as ln2/ke, considering the terminal slope of the decay, where ke is (ln C~day7~ -- ln C~day42~)/(T~day42~ -- T~day\ 7~).

Results {#section17-2046-3758.65.BJR-2017-0276.R1}
=======

Determination of temperature-time profile during PMMA polymerisation {#section18-2046-3758.65.BJR-2017-0276.R1}
--------------------------------------------------------------------

The temperature-time profiles of curing PMMA and the heat exposure programme applied to the antibiotic solutions are shown in [Figure 1](#fig1-2046-3758.65.BJR-2017-0276.R1){ref-type="fig"}. For curing PMMA, the time required from initial mixing until equilibration with the 37°C water bath was 22 minutes. The highest temperature measured during this time was 111.7°C. The replication of the temperature-time curve for the antibiotic solutions also lasted 22 minutes, although the peak temperature was lower (90.7°C) in order to prevent the aqueous solutions from boiling.

![Temperature-time curve of curing polymethyl methacrylate (PMMA) bone cement (large red circle with light grey error bars) and the simulated curve (small circles with black error bars), to which antibiotic solutions were exposed. Measurements were taken every 15 seconds, data represent mean results of a triplicate and error bars represent standard deviation.](bonejointres-06-296-g001){#fig1-2046-3758.65.BJR-2017-0276.R1}

Quantification by LC-MS/MS and FPIA {#section19-2046-3758.65.BJR-2017-0276.R1}
-----------------------------------

The concentration of the antibiotics determined by LC-MS/MS and FPIA, plotted against time, are summarised in [Figure 2](#fig2-2046-3758.65.BJR-2017-0276.R1){ref-type="fig"} for both the regular and the heat groups. Statistically significant differences between both groups have been marked in [Figure 2](#fig2-2046-3758.65.BJR-2017-0276.R1){ref-type="fig"}. Only gentamicin showed a drop in concentration of about 25% due to the initial heat treatment, but remained stable thereafter. Results for clindamycin have been eliminated because the original antibiotic solution apparently decomposed during storage and no drug or degradation product could be measured.

![Thermal stability determined for each antibiotic over time as measured by LC-MS/MS or FPIA. Antibiotic solutions were prepared and maintained at 37°C for 42 days (regular group, solid lines), or first exposed to a heat profile representative of curing bone cement, followed by exposure to body temperature for 42 days (dashed lines). Concentrations in samples taken prior to heat exposure served as 100% reference. Data are means of triplicate experiments. Statistically significant differences between measurements from the regular group and the heat exposed group are marked with an asterisk where appropriate.](bonejointres-06-296-g002){#fig2-2046-3758.65.BJR-2017-0276.R1}

Assessment of antibacterial activity by disk diffusion test {#section20-2046-3758.65.BJR-2017-0276.R1}
-----------------------------------------------------------

ZOI sizes determined by the disk diffusion tests are illustrated for all antibiotic agents in [Figure 3](#fig3-2046-3758.65.BJR-2017-0276.R1){ref-type="fig"}. Again, clindamycin was inactive, suggestive of drug decomposition during storage, and thus not reported. The difference in ZOI between the regular and the heat groups were usually within 1 mm to 2 mm, and thus only results from the regular group are illustrated graphically. Statistically significant differences have been marked in the figure, where appropriate. The only antibiotics that showed a significant reduction of ZOI by 3 mm to 4 mm in the heat group as compared with the body temperature group were amoxicillin with clavulanate (but not amoxicillin alone), cefazolin, cefuroxime, cefotaxime, ceftriaxone and ertapenem, but these differences were only noticeable on day one. Both curves thereafter were virtually identical. Daptomycin showed a marked variability of ZOI over time, which can be explained in part by the limited reliability of the bioassay method for this antibiotic.

![Charts showing thermal stability measured for each antibiotic over time, as determined by bioassay. Results are expressed as means from triplicate experiments. Zone of inhibition (ZOI) indicates diameter of the zone of inhibition, in millimetres. Statistically significant variations of the ZOI relative to starting values are marked with an asterisk where appropriate. Antibiotic solutions were prepared and maintained at 37°C for 42 days (body temperature group). Of note, temocillin and aztreonam have been tested with *E. coli* NCTC 12241, and colistimethate with *P. aeruginosa* PAO1, whereas all other results are from inhibition of *S. aureus* NCTC 12973.](bonejointres-06-296-g003){#fig3-2046-3758.65.BJR-2017-0276.R1}

![Charts showing thermal stability measured for each antibiotic over time, as determined by bioassay. Results are expressed as means from triplicate experiments. Zone of inhibition (ZOI) indicates diameter of the zone of inhibition, in millimetres. Statistically significant variations of the ZOI relative to starting values are marked with an asterisk where appropriate. Antibiotic solutions were prepared and maintained at 37°C for 42 days (body temperature group). Of note, temocillin and aztreonam have been tested with *E. coli* NCTC 12241, and colistimethate with *P. aeruginosa* PAO1, whereas all other results are from inhibition of *S. aureus* NCTC 12973.](bonejointres-06-296-g004){#fig4-2046-3758.65.BJR-2017-0276.R1}

Calculation of degradation half-life *in vitro* {#section21-2046-3758.65.BJR-2017-0276.R1}
-----------------------------------------------

Degradation half-life values calculated from LC-MS/MS and FPIA data are given in [Table II](#table2-2046-3758.65.BJR-2017-0276.R1){ref-type="table"}. When the variability in concentrations was within the analytical variability with profiles essentially parallel to the x-axis, the antibiotic was considered to be stable and marked as such without indicating calculated values. Since no significant differences have been observed between the regular and the heat groups, calculations have been performed with results from the regular group only.

###### 

*In vitro* degradation half-lives, calculated from quantitative data by LC-MS/MS and FPIA as available from the body temperature group

  Antibiotic drugs                     t~1/2~ h (days)
  ------------------------------------ -----------------
  **Penicillins**                      
  Amoxicillin                          150 (6.3)
  Flucloxacillin                       381 (15.9)
  Piperacillin                         410 (17.1)
  Tazobactam                           619 (25.8)
  **Cephalosporins**                   
  Cefazolin                            265 (11.0)
  Cefuroxime                           81 (3.4)
  Ceftriaxone                          261 (10.9)
  Ceftazidime                          176 (7.3)
  Cefepime                             115 (4.8)
  **Carbapenems and monobactams**      
  Imipenem                             72 (3.0)
  Cilastatin                           3202 (133.4)
  Meropenem                            67 (2.8)
  Ertapenem                            96 (4.0)
  **Glycopeptides and lipopeptides**   
  Vancomycin                           Stable
  Daptomycin                           945 (39.4)
  **Aminoglycosides**                  
  Amikacin                             Stable
  Gentamicin                           Stable
  Tobramycin                           Stable
  **Quinolones**                       
  Ciprofloxacin                        Stable
  Levofloxacin                         Stable
  **Various**                          
  Rifampicin                           95 (4.0)
  Linezolid                            Stable
  Colistimethate                       Stable

t~1/2~, half-life

There was no significant difference between samples subjected and those not subjected to the initial heat exposure. "Stable" indicates a degradation below the limit of detection, that is, the observed variability was smaller than the known analytical variability. After a degradation of about 25% induced by the initial short-term heat treatment, gentamicin remains stable (see [Fig. 2](#fig2-2046-3758.65.BJR-2017-0276.R1){ref-type="fig"}). Cilastatin is a renal dehydropeptidase inhibitor co-administered to imipenem.

Discussion {#section22-2046-3758.65.BJR-2017-0276.R1}
==========

Thermal stability is a key feature in determining whether a given antibiotic is suitable for local application.^[@bibr2-2046-3758.65.BJR-2017-0276.R1],[@bibr4-2046-3758.65.BJR-2017-0276.R1]^ The present study provides a comprehensive dataset on the thermal stability of 37 antibiotic agents, monitored over six weeks - a duration which may be targeted for future local antibiotic delivery, as it generally corresponds to the standard duration of treatment of bone and implant-associated infections.^[@bibr17-2046-3758.65.BJR-2017-0276.R1],[@bibr18-2046-3758.65.BJR-2017-0276.R1]^ The potentially deleterious impact on antibiotic integrity of the initial heat released during the curing of PMMA, the carrier material used most commonly in orthopaedic and trauma surgery,^[@bibr3-2046-3758.65.BJR-2017-0276.R1]-[@bibr5-2046-3758.65.BJR-2017-0276.R1]^ has also been examined as a secondary, additional outcome relevant to current clinical practice. Results from this study were focused on applications in orthopaedics, but may also find applications in other clinical settings wherein antibiotic stability is also an issue, such as administration of antibiotics by continuous infusion or via portable elastomeric pumps for parenteral outpatient treatment.^[@bibr11-2046-3758.65.BJR-2017-0276.R1]-[@bibr16-2046-3758.65.BJR-2017-0276.R1],[@bibr21-2046-3758.65.BJR-2017-0276.R1]^ The latter example certainly is an issue since portable devices might reach temperatures of up to 35°C under real-life conditions.^[@bibr21-2046-3758.65.BJR-2017-0276.R1]^

Overall, large differences in antibiotic stability have been observed, ranging from rapid degradation of antibiotics within one to two weeks, to almost complete stability over the entire six-week test period. Not unexpectedly, beta-lactam antibiotics were found to be almost completely degraded over time, with the exception of the monobactam aztreonam, which apparently has a higher stability.^[@bibr16-2046-3758.65.BJR-2017-0276.R1],[@bibr21-2046-3758.65.BJR-2017-0276.R1],[@bibr22-2046-3758.65.BJR-2017-0276.R1]^ Some beta-lactams, namely flucloxacillin, ticarcillin with clavulanate, piperacillin with tazobactam, cefazolin and ceftriaxone, maintained relevant antibacterial activity for up to 21 days. The greater inhibition zones observed in the bioassays for the combination of amoxicillin with clavulanate, compared with amoxicillin alone, might be explained by a synergistic antibacterial effect of the combination.^[@bibr23-2046-3758.65.BJR-2017-0276.R1],[@bibr24-2046-3758.65.BJR-2017-0276.R1]^ On the other hand, clavulanate is known to catalyse the degradation of amoxicillin in aqueous solution.^[@bibr25-2046-3758.65.BJR-2017-0276.R1]^ However, this has not been quantified in our experiment. Temocillin has been reported to yield promising results for the treatment of outpatients using continuous perfusion pumps,^[@bibr13-2046-3758.65.BJR-2017-0276.R1]^ but performed poorly in our study, showing a rapid decay of the antimicrobial activity measured by the Kirby-Bauer assay. Excellent long-term stability has been confirmed in our study for aminoglycosides and glycopeptides, strengthening their suitability and use in the orthopaedic setting.^[@bibr3-2046-3758.65.BJR-2017-0276.R1]-[@bibr5-2046-3758.65.BJR-2017-0276.R1],[@bibr14-2046-3758.65.BJR-2017-0276.R1],[@bibr22-2046-3758.65.BJR-2017-0276.R1]^ Tetracyclines and quinolones were highly thermo-stable according to our study but may not be acceptable for local application due to their reported cellular toxicity.^[@bibr26-2046-3758.65.BJR-2017-0276.R1],[@bibr27-2046-3758.65.BJR-2017-0276.R1]^ Linezolid, trimethoprim with sulfamethoxazole, and, to a lesser extent, fusidic acid, all appeared to have good stability, without known relevant toxicity at the concentrations tested.^[@bibr27-2046-3758.65.BJR-2017-0276.R1]^ Rifampin, while being a cornerstone in the treatment of implant-associated *Staphylococci* infections^[@bibr17-2046-3758.65.BJR-2017-0276.R1]^ showed a rapid decrease of antibacterial activity after two weeks, as measured by bioassay.

Our investigations indicate that the initial short-term temperature elevation mimicking curing of PMMA has limited, if any, impact on antibiotic stability overall. Gentamicin was the only drug that was found to be affected to some extent, with a reduction of about 25% caused by the initial heat treatment. This was not observed for the other aminoglycosides tested. For vancomycin and colistimethate, significant discrepancies were observed in the heat group between the mass spectrometry quantification and bioassay. The prodrug colistimethate needs to be hydrolysed to yield the active colistin, and the extent of such a reaction in the disk diffusion test is uncertain, while the poor diffusion of the active colistin on agar also limits interpretability of the bioassay results, even if colistin resistance can be identified quite reliably with this method.^[@bibr28-2046-3758.65.BJR-2017-0276.R1]^ For vancomycin, possible changes in the solution's matrix after the initial heat treatment may potentially diminish antibiotic bioavailability via alteration of the antibiotic adsorption onto the paper disk and diffusion, hence diminishing the antimicrobial activity.

The quantification of LC-MS/MS and FPIA provides precise drug concentrations, and allows us to determine the *in vitro* degradation half-lives ([Table II](#table2-2046-3758.65.BJR-2017-0276.R1){ref-type="table"}). However, such methods were not available for all antibiotics, notably the macrolides/ketolides and the tetracyclines/glycylcyclines ([Table I](#table1-2046-3758.65.BJR-2017-0276.R1){ref-type="table"}). Disk diffusion tests have been used for a qualitative, rather than quantitative, assessment of activity for these antibiotics. The establishment of calibration curves to enable semi-quantitative measurement of such a large number of antibiotics would have been technically challenging, relatively imprecise, and interpretation would have been limited to narrow ranges of concentrations.^[@bibr29-2046-3758.65.BJR-2017-0276.R1]^ Besides, for glycopeptides and daptomycin, the disk diffusion approach can be used only for ascertaining the presence of antibacterial activity.^[@bibr20-2046-3758.65.BJR-2017-0276.R1],[@bibr30-2046-3758.65.BJR-2017-0276.R1]^ More generally, the comparison with recommended breakpoints for susceptibility testing using bioassays is also limited since, for most antibiotics in our experiment, quantities that have to be loaded onto paper disks would exceed the starting concentration, which had been defined in consideration of local toxicity issues.^[@bibr19-2046-3758.65.BJR-2017-0276.R1],[@bibr20-2046-3758.65.BJR-2017-0276.R1],[@bibr27-2046-3758.65.BJR-2017-0276.R1],[@bibr30-2046-3758.65.BJR-2017-0276.R1]^

A strength of this study is that two different analytical approaches have been used. Precise quantification of the most commonly prescribed antibiotic agents has been performed by LC-MS/MS or FPIA, while antibacterial activity has been ascertained for all antibiotics by disk diffusion assays. Overall, the bioassays were generally congruent with the quantitative analysis by LC-MS/MS or FPIA. The LC-MS/MS method reveals that gentamicin was in part degraded by the initial heat treatment, while this 25% drop in concentration could not be detected by the less sensitive disk diffusion assay. Thus, tobramycin might be a more appropriate antibiotic to associate with PMMA, as it has an equivalent spectrum of activity^[@bibr31-2046-3758.65.BJR-2017-0276.R1]^ but improved stability in our experiment. Of course, tissue penetration is an additional factor in the performance of any antibiotic, be it locally or systemically applied, even if difficult to interpret.^[@bibr32-2046-3758.65.BJR-2017-0276.R1],[@bibr33-2046-3758.65.BJR-2017-0276.R1]^ Data on antibiotic penetration of tobramycin *versus* gentamicin are limited,^[@bibr32-2046-3758.65.BJR-2017-0276.R1]^ but the expectation would be that it would be similar due to very similar physicochemical properties.^[@bibr34-2046-3758.65.BJR-2017-0276.R1]^ Even if all assays had been performed as a batch at the end of the experiment, no degradation of the antibiotics during storage would be expected, even for the more fragile beta-lactams, as the samples have been kept continuously at -80°C.^[@bibr35-2046-3758.65.BJR-2017-0276.R1]^

Limitations of our experimental setting have to be acknowledged, particularly regarding the heat exposure mimicking the exothermic process taking place during the curing of bone cement. The temperature profile recorded in our study is specific to a given cement and form. Cements with other specifications and other quantities and forms may yield different temperature-time profiles.^[@bibr36-2046-3758.65.BJR-2017-0276.R1]^ The experimental design, i.e. subjecting an aqueous solution to a steam autoclave, may not have reproduced a temperature-time profile that strictly followed the one observed during the solid-state cement curing as boiling of the test solution had to be avoided. The use of pressure-resistant closed containers might allow testing of the potential effect of higher temperatures, but these were not available for the required volumes. While no discrepancies were observed between LC-MS/MS or FPIA and disk diffusion tests, disk diffusion data are available for more time points within the study period, while quantification assays suffer from a gap between day seven and day 42. The schedule had been chosen to adapt best to exponential degradation of unstable drugs, while still being able to describe long-term stability. The results, however, do not indicate that a certain degradation profile would not have been detected. Another issue could be the fact that a number of antibiotics were tested in combination, however, the effects of these combinations cannot be evaluated as the individual drugs were not tested in isolation. Last, but not least, the test samples were solutions of antibiotics, also containing the various components of the pharmaceutical preparations such as preservatives, buffers and stabilising agents that reflect only partially the interactions with biological solutions and the various reactions occurring during cement curing.

In conclusion, our study provides information of interest not only for local application of antibiotics in orthopaedic and trauma surgery, but also in other medical specialties that require prolonged antibiotic exposure and for which drug stability is also an issue. In order to maximise the applicability of our data, we did not test elution from any material, or measure degradation at room or refrigerated temperatures. Our experiments have allowed the identification of classes of antibiotics or specific agents deemed useful for further investigation because of favourable *in vitro* stability. Additionally, this dataset is relevant for the next generation of antibiotic carriers as it provides data pertinent to the thermal stability of a range of antibiotics that may be considered for this use. Nevertheless, any future studies on antibiotic carriers should include careful assessment of antibiotic release kinetics, both *in vitro* and *in vivo*.
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